Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Amgen vs. Johnson & Johnson

TheMotleyFool

0 0

Better Buy: Amgen vs. Johnson & JohnsonPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Amgen (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ) have quite a few things in common. They both rank among the most attractive healthcare dividend stocks. Both companies have long track records of success. Amgen and J&J each have promising new products along with older products that are weighing on sales.

With less than two weeks remaining in 2019, Amgen has been the bigger winner so far this year, more than doubling the gain delivered by Johnson & Johnson. But which of these two healthcare stocks is the better pick for long-term investors? Here's how Amgen and J&J compare.

Image source: Getty Images.

Source Fool.com

Like: 0

AMGN

Share